Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
暂无分享,去创建一个
M. Ross | I. Puzanov | M. Milhem | H. Kaufman | O. Hamid | J. Glaspy | F. Collichio | L. Cranmer | J. Chesney | R. Andtbacka | Y. Saenger | Jenny J. Kim | Lisa Chen